169 related articles for article (PubMed ID: 38610989)
1. Synergistic Effects of the RAR
Fleischmann M; Bechwar J; Voigtländer D; Fischer M; Schnetzke U; Hochhaus A; Scholl S
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610989
[TBL] [Abstract][Full Text] [Related]
2. A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia.
Candoni A; Coppola G
Hematol Rep; 2024 Apr; 16(2):244-254. PubMed ID: 38651453
[TBL] [Abstract][Full Text] [Related]
3. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Fiskus W; Boettcher S; Daver N; Mill CP; Sasaki K; Birdwell CE; Davis JA; Takahashi K; Kadia TM; DiNardo CD; Jin Q; Qi Y; Su X; McGeehan GM; Khoury JD; Ebert BL; Bhalla KN
Blood Cancer J; 2022 Jan; 12(1):5. PubMed ID: 35017466
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
Juul-Dam KL; Shukla NN; Cooper TM; Cuglievan B; Heidenreich O; Kolb EA; Rasouli M; Hasle H; Zwaan CM
Eur J Med Genet; 2023 Dec; 66(12):104869. PubMed ID: 38174649
[TBL] [Abstract][Full Text] [Related]
5. Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML.
Ling Q; Zhou Y; Qian Y; Qian J; Zhang Y; Wang J; Zhu Y; Zhou Y; Wei J; Yang C; Sun J; Yu W; Jin J; Zhang X
Biomark Res; 2023 Dec; 11(1):105. PubMed ID: 38053201
[TBL] [Abstract][Full Text] [Related]
6. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
Bourgeois W; Cutler JA; Aubrey BJ; Wenge DV; Perner F; Martucci C; Henrich JA; Klega K; Nowak RP; Donovan KA; Boileau M; Wen Y; Hatton C; Apazidis AA; Olsen SN; Kirmani N; Pikman Y; Pollard JA; Perry JA; Sperling AS; Ebert BL; McGeehan GM; Crompton BD; Fischer ES; Armstrong SA
Blood; 2024 Apr; 143(15):1513-1527. PubMed ID: 38096371
[TBL] [Abstract][Full Text] [Related]
7. Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.
de Botton S; Cluzeau T; Vigil C; Cook RJ; Rousselot P; Rizzieri DA; Liesveld JL; Fenaux P; Braun T; Banos A; Jurcic JG; Sekeres MA; Savona MR; Roboz GJ; Bixby D; Madigan K; Volkert A; Stephens K; Kang-Fortner Q; Baker K; Paul S; McKeown M; Carulli J; Eaton M; Hodgson G; Fiore C; Kelly MJ; Roth DA; Stein EM
Blood Adv; 2023 May; 7(9):1858-1870. PubMed ID: 36477975
[TBL] [Abstract][Full Text] [Related]
8. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Issa GC; Aldoss I; DiPersio J; Cuglievan B; Stone R; Arellano M; Thirman MJ; Patel MR; Dickens DS; Shenoy S; Shukla N; Kantarjian H; Armstrong SA; Perner F; Perry JA; Rosen G; Bagley RG; Meyers ML; Ordentlich P; Gu Y; Kumar V; Smith S; McGeehan GM; Stein EM
Nature; 2023 Mar; 615(7954):920-924. PubMed ID: 36922593
[TBL] [Abstract][Full Text] [Related]
9. Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation.
Thomas X
Oncol Ther; 2024 Mar; 12(1):57-72. PubMed ID: 38300432
[TBL] [Abstract][Full Text] [Related]
10. Targeting the undruggable: menin inhibitors ante portas.
Dempke WCM; Desole M; Chiusolo P; Sica S; Schmidt-Hieber M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9451-9459. PubMed ID: 37103568
[TBL] [Abstract][Full Text] [Related]
11. Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold?
Swaminathan M; Bourgeois W; Armstrong SA; Wang ES
Cancer J; 2022 Jan-Feb 01; 28(1):62-66. PubMed ID: 35072375
[TBL] [Abstract][Full Text] [Related]
12. Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with
Stein EM; de Botton S; Cluzeau T; Pigneux A; Liesveld JL; Cook RJ; Rousselot P; Rizzieri DA; Braun T; Roboz GJ; Lebon D; Heiblig M; Baker K; Volkert A; Paul S; Rajagopal N; Roth DA; Kelly M; Peterlin P
Leuk Lymphoma; 2023 Dec; 64(12):1992-2001. PubMed ID: 37571998
[TBL] [Abstract][Full Text] [Related]
13. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
[TBL] [Abstract][Full Text] [Related]
14. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract][Full Text] [Related]
15. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.
Balusu R; Fiskus W; Rao R; Chong DG; Nalluri S; Mudunuru U; Ma H; Chen L; Venkannagari S; Ha K; Abhyankar S; Williams C; McGuirk J; Khoury HJ; Ustun C; Bhalla KN
Blood; 2011 Sep; 118(11):3096-106. PubMed ID: 21719597
[TBL] [Abstract][Full Text] [Related]
16. Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia.
Uckelmann HJ; Haarer EL; Takeda R; Wong EM; Hatton C; Marinaccio C; Perner F; Rajput M; Antonissen NJC; Wen Y; Yang L; Brunetti L; Chen CW; Armstrong SA
Cancer Discov; 2023 Mar; 13(3):746-765. PubMed ID: 36455613
[TBL] [Abstract][Full Text] [Related]
17. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
Nguyen D; Kantarjian HM; Short NJ; Qiao W; Ning J; Cuglievan B; Daver NG; DiNardo CD; Jabbour EJ; Kadia TM; Borthakur G; Garcia-Manero G; Konopleva MY; Andreeff M; Ravandi-Kashani F; Sasaki K; Issa GC
Cancer; 2023 Jun; 129(12):1856-1865. PubMed ID: 36892949
[TBL] [Abstract][Full Text] [Related]
18. The MLL-Menin Interaction is a Therapeutic Vulnerability in
Rasouli M; Blair H; Troester S; Szoltysek K; Cameron R; Ashtiani M; Krippner-Heidenreich A; Grebien F; McGeehan G; Zwaan CM; Heidenreich O
Hemasphere; 2023 Aug; 7(8):e935. PubMed ID: 37520776
[TBL] [Abstract][Full Text] [Related]
19. The effect of small molecule inhibitor NSC348884 on nucleophosmin 1-mutated acute myeloid leukemia cells.
Zhu JF; Han LL; Ma Y; Wang YX; Zhang F
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(19):9145-9151. PubMed ID: 37843328
[TBL] [Abstract][Full Text] [Related]
20. INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia.
Jin H; Yang L; Wang L; Yang Z; Zhan Q; Tao Y; Zou Q; Tang Y; Xian J; Zhang S; Jing Y; Zhang L
J Exp Clin Cancer Res; 2018 Jan; 37(1):8. PubMed ID: 29343273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
